Clinical Study of EarlyTect® Colon CancerIn a pivotal clinical study, EarlyTect® Colon Cancer Test has been proven to be able to diagnose colorectal cancer with 90.2% sensitivity and 90.2% specificity, and 89.1% sensitivity for early stages (0-II) on 585 subjects at Severance Hospital and Health Promotion Center of Severance Hospital. In addition, the sensitivity is not associated with sex, age, tumor stage and tumor location. EarlyTect® Colon Cancer
Sensitivity of EarlyTect® CRC Test to clinical stages
In a pilot clinical study, EarlyTect® Bladder Cancer Test has been shown to be able to diagnose bladder cancer with 84.0% sensitivity and 94.0% specificity,
and 74.0% sensitivity for pTa, early stages of bladder cancer, on 574 hematuria subjects at Chungnam National University Hospital, Konyang University Hospital and Daejeon Catholic St. Mary's Hospital.
In a pivotal clinical study, EarlyTect® Lung Cancer Test has been proven to be able to diagnose lung cancer with 77.8% sensitivity and 92.3% specificity, and 62.2% sensitivity for early stages (I-II) on 522 subjects at Kyungpook National University Chilgok Hospital. In addition, the sensitivity is not associated with tumor stage, smoking history, or age.